Tolcapone added to Levodopa in stable Parkinsonian patients: A double-blind placebo-controlled study

Movement Disorders

Volumn 12, Issue 6, 1997, Pages 928-934

  Dupont, Erik ^a,f   Burgunder, Jean Marc ^b,f   Findley, Leslie J ^c,f   Olsson, Jan Edvin ^d,f   Dorflinger, Ernest ^e   Beiske, Antonie ^f   Jindley, Leslie ^f   Godwin Austen, Richard ^f   Hess, Christian Walter ^f   Home, Malcolm ^f   Larsen, Jan Petter ^f   Ekstedt, Bo ^f   Mikkelsen, Bent ^f   Palhagen, Sven ^f   Palm, Ragnar ^f   Tysnes, Ole Björn ^f   Van Der Linden, Chris ^f   Wermuth, Lene ^f  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF BERN   (Switzerland)

^c OLDCHURCH HOSPITAL   (United Kingdom)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e HOFFMANN LA ROCHE INC   (United States)

^f Århus Kommunehospital ^*

Author keywords

Levodopa; Motor fluctuations; Parkinson's disease; Tolcapone; Wearing off phenomenon

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA; TOLCAPONE;

ADULT; AGED; AGITATION; ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DREAMING; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; DYSTONIA; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT OUTCOME; TREMOR; VERTIGO; VOMITING;

EID: 0030695512     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870120615     Document Type: Article

References (10)

1. Zürcher G, Colzi A, Da Prada M. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J Neural Transm Suppl 1990; 32:375-380.
2. Da Prada M, Zürcher G, Kettler R, Colzi A. New therapeutic strategies in Parkinson's disease: inhibition of MAO-B by Ro 19-6327 and of COMT by Ro 40-7592. Adv Behav Biol 1991;39:723-732.
3. Borgulya J, Da Prada M, Dingemanse J, Scherschlicht R, Sehläppi B, Zürcher G. Ro 40-7592: catecholamine-O-methyltransferase (COMT) inhibitor. Drugs Future 1991;16:719-721.
4. Zürcher G, Dingemanse J, Da Prada M. Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. In: Agnoli A, Campanella G, eds. New Developments in Therapy of Parkinson's Disease. Rome: John Libbey, 1991:37-43.
5. Dingemanse J, Jorga KM, Schmitt M, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995;57:508-517.
6. Dingemanse J, Jorga K, Zürcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-262.
7. Dingemanse J, Jorga K, Zürcher G, et al. Multiple-dose clinical pharmacology of the catechol-O-methyltransferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996;50:47-55.
8. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
9. Rolan PE. Plasma protein binding displacement interactions: why are they still regarded as clinically important? Br J Clin Pharmacol 1994;37;125-128.
10. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996;19:283-296.